EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy

Pak On Patrick Yee, Hayley Hoi Ning Ip, Michael Kwan Leung Yu, Pui Kei Cheng, Wilfred Hing Sang Wong iD, Patrick Pak Hei Ng, Nathan Sheung Tat Kwong, Priscillia Lam, Mei Wun Cheung, Angel Tung, Stephen Chan, Shirley Ng and 5 more

European Journal of Neurology · 2026-04 · 33 (4)

DOI: 10.1111/ene.70574 ↗

At a glance

Journal article in European Journal of Neurology, published online on 2026-03-24. Written by Pak On Patrick Yee and 16 co-authors. Institution: Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China. Major MEDLINE topics: Muscular Atrophy, Spinal, Sulfonamides. Cited 1 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Donation Funding.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Risdiplam, an oral disease‐modifying therapy, has demonstrated safety and efficacy in clinical trials, but real‐world data from Asia are limited.

Methods

This prospective study followed 34 symptomatic SMA patients (24 adults, 10 children) over 36 months of risdiplam treatment. The cohort included 5 patients with SMA type 1, 25 with SMA type 2, and 4 with SMA type 3, with ages ranging from 6.9 to 50.9 years. Most (91%) were wheelchair users, and 74% had scoliosis managed by bracing or spinal surgery. Twenty‐five patients (22 adults, 3 children) were treatment naïve, and 9 patients (2 adults, 7 children) switched from nusinersen. Motor function was assessed at baseline, 6, 12, 24, and 36 months using MFM‐32, RULM, ATEND, and HFMSE. In pediatric patients, HRQOL was evaluated using PedsQL Neuromuscular Module and PedsQL Generic Core scale. HRQOL of their parents was assessed with PedsQL Family Impact Module.

Results

After 36 months, MFM‐32 score was significantly improved in those switching therapies [ p = 0.042], while both MFM‐32 and RULM scores were significantly improved in treatment‐naïve group [ p = 0.005 and p = 0.043]. Parents experienced HRQOL gains in their Physical domain (2 years: PedsQL Family Impact Module, p = 0.038). Pediatric patients showed improvement in the Communication domain (3 years: PedsQL Neuromuscular Module, p = 0.042). Risdiplam was generally well tolerated; however, two adults discontinued due to adverse effects. Moreover, two adult patients died during treatment.

Conclusions

This study fills Asian real‐world data gaps, stresses the importance in monitoring in severe SMA, and underscores the need for larger, long‐term safety and efficacy studies.

Subjects

MeSH terms (MEDLINE)

Muscular Atrophy, SpinalSulfonamidesHumansFemaleMaleChildAdultAdolescentMiddle AgedYoung AdultQuality of LifeProspective StudiesTreatment OutcomeOligonucleotidesAzo CompoundsPyrimidines

Author keywords

health‐related quality of lifemotor functionpatient‐reported outcomerisdiplamspinal muscular atrophy

Substances

RisdiplamnusinersenSulfonamidesOligonucleotidesAzo CompoundsPyrimidines

Authors and institutions

  • Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong SAR, China.
  • Department of Physiotherapy, Queen Mary Hospital, Hong Kong SAR, China.
  • Allied Health Department (Physiotherapy), Hong Kong Children's Hospital, Hong Kong SAR, China.
  • Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong SAR, China.
  • Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China.

ORCID profiles: Wilfred Hing Sang Wong, Sophelia Hoi Shan Chan

Funding

  • Donation Funding

Cite

APA

Yee, P. O. P., Ip, H. H. N., Yu, M. K. L., Cheng, P. K., Wong, W. H. S., Ng, P. P. H., Kwong, N. S. T., Lam, P., Cheung, M. W., Tung, A., Chan, S., Ng, S., Yeung, W. L., Wong, S., Gao, Y., Pang, S., & Chan, S. H. S. (2026). Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70574

Vancouver

Yee POP, Ip HHN, Yu MKL, Cheng PK, Wong WHS, Ng PPH, et al. Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70574

BibTeX
@article{Yee2026,
  author = {Yee, Pak On Patrick and Ip, Hayley Hoi Ning and Yu, Michael Kwan Leung and Cheng, Pui Kei and Wong, Wilfred Hing Sang and Ng, Patrick Pak Hei and Kwong, Nathan Sheung Tat and Lam, Priscillia and Cheung, Mei Wun and Tung, Angel and Chan, Stephen and Ng, Shirley and Yeung, Wai Lan and Wong, Sheila and Gao, Yuen and Pang, Shirley and Chan, Sophelia Hoi Shan},
  title = {Risdiplam Impact in Treatment Naïve and Non‐Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {4},
  doi = {10.1111/ene.70574}
}
Start for free →